Join Meeting Now

Your data is secure and never shared.

United States
August 2026

United States Surgical Equipment Market Size, Share & Forecast, By Product Type, Care Setting & Technology, 2025–2032

2032

The United States Surgical Equipment Market worth USD 40,800 million in 2025 is growing at a CAGR of 6.50% to reach USD 59,734 million by 2031. Stryker Corporation, Intuitive Surgical, Inc., Johnson & Johnson MedTech, Boston Scientific Corporation and STERIS plc are the major companies operating in this market.

Report Details

Base Year

2025

Pages

86

Region

United States

Author

Ken Research

Product Code
KR-RPT-V02-08445

CHAPTER 1 - MARKET SUMMARY

Market Overview

The United States Surgical Equipment Market operates through a procedure-driven demand model in which recurring instruments, consumables and service revenue sit alongside periodic capital purchases. The underlying demand base is approximately 35.0 Mn surgical operations in 2025, with general and gastrointestinal surgery representing the largest procedure-linked equipment wallet in the supplied demand-side build. This creates substantial recurring revenue opportunities around high-frequency surgical workflows.

Supply is concentrated around large integrated medtech companies but delivered through a highly distributed hospital and ambulatory infrastructure. The United States has more than 43,800 hospital operating rooms in 2025, while the ambulatory surgery ecosystem includes 9,000+ active centers. This broad installed base makes service coverage, capital financing, instrument availability, sterile-processing support and account-level contracting central competitive capabilities.

Market Value

USD 40,800 Mn

2025

Dominant Region

South

2025 facility-footprint proxy

Dominant Segment

Gastrointestinal and General Surgery

2025 demand pool

Total Number of Players

18+ named large players plus fragmented specialist suppliers

Future Outlook

The United States Surgical Equipment Market is expected to move from its 2025 base into a higher-technology revenue mix led by robotic-assisted surgery, minimally invasive platforms, visualization systems, connected operating rooms and procedure-linked disposable products. The historical 2020–2025 normalized trajectory implies a 5.6% CAGR, while the supplied 2025–2030 forecast accelerates as technology intensity rises faster than procedure volume. The model extends this trajectory to USD 59,734 Mn in 2031, reflecting continued capital conversion, higher consumables attachment and selective pricing.

Core surgical volume is expected to expand more slowly than revenue, moving from 35.0 Mn operations in 2025 to approximately 37.27 Mn in 2031. Consequently, implied equipment spend per operation rises from about USD 1,166 to USD 1,603 as robotics, navigation, advanced energy, visualization and reprocessing content increase. The resulting 2026–2031 value CAGR is 6.5%. Reimbursement pressure and health-system purchasing power temper growth, while recurring consumables and service models improve revenue visibility for scaled suppliers.

6.5%

Forecast CAGR

USD 59,734 Mn

2030 Projection

Base Year

2025

Historical Period

2020–2025

Forecast Period

2026–2031

Historical CAGR

5.6%

CHAPTER 2 - SCOPE OF REPORT

Scope of the Market

Click to Explore Interactive Mind Map

CHAPTER 3 - Key Stakeholders

Key Target Audience

Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.

Investors

growth, recurring consumables, robotics penetration, margin, concentration, capex

Corporates

procurement, procedure intensity, service uptime, leasing, utilization, standardization

Government

FDA compliance, supply resilience, tariffs, access, safety, competition

Operators

OR throughput, instrument turns, reprocessing, utilization, uptime, staffing

Financial institutions

equipment financing, lease yield, credit, reimbursement, demand stability

What You'll Gain

  • Market sizing and trajectory
  • Robotics competition benchmarking
  • ASC demand and access
  • Procurement and pricing levers
  • Regulatory and tariff exposure
  • Supplier concentration and risk

80+

Pages of insights

CHAPTER 4 - Market Size & Growth

Market Size, Growth Forecast and Trends

This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.

Historical & Projected Market Size ($ Million)

Year-over-Year Growth Rate (%)

Market Value vs Volume Growth (%)

Historical Market Performance

The normalized historical series, anchored to the authoritative 2025 market estimate, indicates that market value increased from USD 31,100 Mn in 2020 to USD 40,800 Mn in 2025. Value expanded faster than surgical operation volume because advanced visualization, robotic instruments, energy devices and capital-equipment intensity raised equipment content per case. Surgical operations increased from approximately 30.8 Mn to 35.0 Mn over the same period, while implied equipment spend per operation rose from roughly USD 1,010 to USD 1,166. The pattern shows a market driven by both procedure recovery and richer technology mix.

Forecast Market Outlook

Forecast growth is expected to remain value-led rather than volume-led. The supplied model projects 2026–2030 growth of 6.9%, 6.8%, 6.7%, 6.6% and 6.3%, respectively, while surgical operation growth slows from 1.3% to 0.9%. Extending that trajectory produces USD 59,734 Mn in 2031 and a 6.5% CAGR from 2026. Implied equipment spend per operation reaches about USD 1,603 by 2031, demonstrating that robotic conversion, advanced energy, navigation, single-use products and service attachment remain more important to value creation than underlying procedure growth alone.

CHAPTER 5 - Market Data

Market Breakdown

The United States Surgical Equipment Market combines modest procedure-volume expansion with faster growth in technology content, recurring consumables and capital-platform intensity. The following operating spine links market value to surgical operations, equipment spend per procedure and a normalized technology-intensity indicator.

Market Breakdown

Historical Data (2020-2024) • Base Data (2025) • Forecast Data (2026-2031)

Year
Market Size (USD Mn)
YoY Growth (%)
Surgical Operations (Mn)
Spend per Operation (USD)
Technology Intensity Index (2025=100)
Period
2020$31,100 Mn+-30.801,010
$#%
Forecast
2021$33,150 Mn+6.6%31.901,039
$#%
Forecast
2022$35,100 Mn+5.9%33.001,064
$#%
Forecast
2023$37,150 Mn+5.8%33.901,096
$#%
Forecast
2024$38,850 Mn+4.6%34.501,126
$#%
Forecast
2025$40,800 Mn+5.0%35.001,166
$#%
Forecast
2026$43,610 Mn+6.9%35.461,230
$#%
Forecast
2027$46,573 Mn+6.8%35.891,298
$#%
Forecast
2028$49,690 Mn+6.7%36.281,370
$#%
Forecast
2029$52,970 Mn+6.6%36.641,446
$#%
Forecast
2030$56,300 Mn+6.3%36.971,523
$#%
Forecast
2031$59,734 Mn+6.1%37.271,603
$#%
Forecast

Surgical Operations

35.0 Mn operations (2025, United States). Procedure volume provides the recurring usage base for instruments, energy devices, scopes, robotic accessories and reprocessing. The model reaches 37.27 Mn operations by 2031, making installed-base monetization more important than pure procedure growth.

Spend per Operation

USD 1,166 per operation (2025, United States). The rise toward USD 1,603 by 2031 reflects a richer mix of robotics, digital visualization, navigation, specialty capital and single-use products, making technology penetration the principal value-growth lever.

Technology Intensity Index

100 index points (2025, United States). The index captures the shift from conventional instrumentation toward minimally invasive, robotic and digitally integrated operating-room workflows. Supplier economics increasingly depend on placements that generate recurring instrument, accessory, software and service revenue.

CHAPTER 6 - Segmentation

Market Segmentation Framework

Comprehensive analysis across seven commercially relevant dimensions provides a structured view of product mix, surgical settings, users, clinical applications, procurement routes, technology adoption and geographic demand.

No of Segments

7

Dominant Segment

Disease Area - Gastrointestinal and General Surgery

Fastest Growing Segment

Technology - Robotic-Assisted Surgical Systems

Product Type

Handheld Surgical Instruments
$%
Electrosurgical and Energy Devices
$%
Endoscopy and Visualization Systems
$%
Robotic, OR Capital and Reprocessing Equipment
$%

Care Setting

Acute-Care Hospitals
$%
Ambulatory Surgery Centers
$%
Specialty Surgical Hospitals
$%
Office-Based Procedure Centers
$%

End User

Surgeons and Proceduralists
$%
Perioperative Nursing Teams
$%
Sterile Processing Departments
$%
Supply Chain and Value Analysis Teams
$%

Disease Area

Gastrointestinal and General Surgery
$%
Musculoskeletal and Neuro Surgery
$%
Cardiovascular and Thoracic Surgery
$%
Ophthalmic, Urologic and Women's Health Surgery
$%

Channel

Direct OEM Contracts
$%
Group Purchasing Organization Contracts
$%
Authorized Distributors
$%
Capital Leasing and Managed Services
$%

Technology

Conventional Manual Instrumentation
$%
Minimally Invasive and Laparoscopic Systems
$%
Robotic-Assisted Surgical Systems
$%
Digital OR, Navigation and AI-Enabled Systems
$%

Geography

Northeast
$%
Midwest
$%
South
$%
West
$%

Key Segmentation Takeaways

Disease Area - Gastrointestinal and General Surgery

General and GI surgery forms the largest demand pool in the supplied 2025 procedure build, reflecting high procedure frequency and broad use of laparoscopy, robotic instruments, stapling, energy systems and visualization. Suppliers with integrated portfolios can capture capital, recurring consumable and service revenue from the same procedural workflow.

Technology - Robotic-Assisted Surgical Systems

Robotic-assisted surgery is the fastest-changing competitive domain because each system placement expands demand for instruments, accessories, maintenance, training and software. Multi-vendor competition increases platform choice while preserving a recurring-revenue model linked to procedure utilization, making installed-base growth and consumables attachment critical strategic KPIs.

CHAPTER 7 - Regional Analysis

Regional and Peer Market Analysis

The United States is the largest market among the selected advanced-economy peers. The headline report uses the broad full-stack market definition, while the comparison table uses published narrow-scope surgical-equipment estimates for cross-country comparability because peer-country broad-stack estimates are not consistently disclosed.

Focus Country Ranking:

Focus Country Market Size:

Focus Country CAGR:

Regional and Peer Market Analysis (Current Year)

Regional and Peer Market Analysis Comparison

MetricUnited StatesCanadaGermanyJapanUnited Kingdom
Market Size, Narrow-Scope Peer Proxy (USD Bn, 2025)7.341.571.341.080.85
CAGR (%)6.5% report scope8.1%8.1%8.8%7.5%
Population Aged 65+ Share (%, latest comparable)18.0%19.5%23.2%29.3%19.0%
Hospital Beds per 1,000 People (latest comparable)2.82.57.712.62.4

Market Position

The United States ranks first among the selected peers, with a published narrow-scope benchmark of USD 7.34 Bn in 2025, before adding robotics, broader OR capital and reprocessing included in this report.

Growth Advantage

Peer markets remain attractive but materially smaller: Canada is approximately USD 1.57 Bn in 2025 and Germany approximately USD 1.34 Bn under comparable narrow-scope definitions.

Competitive Strengths

The United States combines a large procedure base with 43,800+ hospital operating rooms and 9,000+ active ASCs, supporting high service density, capital utilization and recurring instrument demand.

CHAPTER 8 - INDUSTRY ANALYSIS

Growth Drivers, Challenges & Opportunities

Comprehensive analysis of key factors shaping the United States Surgical Equipment Market, including technology conversion, site-of-care migration, reimbursement constraints, procurement economics and emerging platform opportunities.

Growth Drivers

Robotic Surgery Conversion Raises Equipment Content per Procedure

  • Intuitive reported approximately 3.153 Mn da Vinci procedures in 2025 worldwide, demonstrating the scale of the installed ecosystem that monetizes instruments, accessories, service and systems.
  • Approximately 870 da Vinci 5 systems were placed in 2025 worldwide, illustrating how next-generation platform replacement can create capital purchases while sustaining recurring procedure revenue.
  • Medtronic received FDA clearance for Hugo in December 2025 for urologic procedures, a category associated with approximately 230,000 U.S. procedures annually, broadening competitive platform choice.

Ambulatory Surgery Migration Expands Distributed Equipment Demand

  • More than 6,500 Medicare-certified ASCs in 2025 create a large standardized outpatient customer universe for instruments, endoscopy, energy systems and specialty capital equipment.
  • The ASC footprint includes approximately 18,000+ operating rooms in 2025, creating recurring demand for room-level equipment, sterile processing and procedure-specific consumables outside acute-care hospitals.
  • Medicare's 2.9% ASC payment update for CY2025 supports nominal reimbursement growth while preserving pressure on capital productivity and per-case economics.

Aging and Surgical Intensity Sustain the Procedure Base

  • The historical CDC ambulatory baseline recorded 34.7 Mn ambulatory surgery visits in 2006, supporting the structural depth of outpatient procedural activity underlying today's market.
  • The United States has 43,800+ hospital operating rooms in 2025, providing a broad installed-capital base requiring replacement, maintenance, instrumentation and sterile-processing support.
  • The report's surgical-operation model moves from 35.0 Mn in 2025 to 37.27 Mn in 2031; the strategic value therefore comes from monetizing a large, resilient procedure base rather than relying on high unit-volume growth.

Market Challenges

Reimbursement and Procurement Pressure Limit Price Realization

  • ASC payment is organized through Medicare prospective-payment rules, requiring suppliers to align premium equipment economics with facility reimbursement and throughput gains rather than technology features alone.
  • The United States hospital medical and surgical supply-cost base reached approximately USD 57.0 Bn in 2025, making procurement savings and value-analysis controls economically material for health systems.
  • Large GPO and health-system contracts can consolidate purchasing across thousands of facilities, increasing buyer leverage and making portfolio breadth, service performance and contracting discipline central margin-protection capabilities.

Import Exposure and Tariff Policy Add Supply-Chain Volatility

  • U.S. HS 901890 exports were approximately USD 17.93 Bn in 2024, making the category a major two-way trade flow rather than a purely domestic supply chain.
  • The broad HS 901890 balance implies approximately USD 2.74 Bn of net imports in 2024, so component origin, inventory buffers and supplier diversification can affect procurement economics.
  • Intuitive's January 2026 guidance estimated tariff effects at approximately 1.2% of revenue, plus or minus 10 basis points, demonstrating that trade policy can materially influence medtech gross-margin planning.

Regulatory Authorization Raises Entry Costs for Advanced Platforms

  • FDA guidance emphasizes that robotic-assisted systems remain under direct surgeon control, reinforcing the need for extensive human-factors, clinical-performance and training evidence.
  • Hugo's December 2025 FDA clearance demonstrates that entry requires lengthy development and regulatory investment before commercial access to specific U.S. surgical indications.
  • Intuitive placed 1,721 systems worldwide in 2025, illustrating the scale of installed-base investment that new entrants must compete against after obtaining authorization.

Market Opportunities

Multi-Vendor Robotic Competition Expands the Addressable Platform Pool

  • Each robotic placement creates recurring demand for instruments, accessories, service and training, while Intuitive's USD 6.02 Bn instruments and accessories revenue in 2025 worldwide demonstrates the scale of this model.
  • OEMs, hospitals, surgeons, component suppliers and service providers benefit as multiple platforms compete for a U.S. procedure base of approximately 35.0 Mn operations in 2025.
  • Broader adoption requires FDA-authorized indications, trained surgical teams and compelling utilization economics across a hospital infrastructure exceeding 43,800 operating rooms in 2025.

Recurring Consumables and Service Can Outgrow Capital Revenue

  • Converting capital placements into multi-year instrument, accessory, maintenance and software streams can increase lifetime account value without requiring equivalent growth in new procedure volume.
  • Scaled suppliers with direct field service and clinical-support networks can monetize recurring workflows across 9,000+ U.S. ASCs in 2025 as well as hospital systems.
  • Suppliers must demonstrate utilization and total-cost benefits because equipment spend per operation rises from approximately USD 1,166 in 2025 under the report model.

ASC-Specific Equipment, Reprocessing and Financing Create Whitespace

  • Compact imaging, energy, endoscopy, sterilization and leased capital systems can capture outpatient procedure migration without requiring hospital-scale room configurations.
  • OEMs, specialty distributors, leasing providers and reprocessing suppliers can address an ASC infrastructure exceeding 18,000 operating rooms in 2025.
  • Products must align with outpatient reimbursement, room turnover and lower-capex requirements while maintaining FDA compliance and clinical performance under the CY2025 2.9% ASC payment update.

CHAPTER 9 - Competitive Landscape

Competitive Landscape Overview

The United States Surgical Equipment Market is concentrated among scaled medtech suppliers in premium platforms while retaining a fragmented specialist tail. The pre-calculated company attribution indicates CR5 of 60.1% and CR10 of 78.0% in 2025.

Market Share Distribution

Stryker Corporation
Intuitive Surgical, Inc.
Johnson & Johnson MedTech
Boston Scientific Corporation

Top 5 Players

1
Stryker Corporation
!$*
2
Intuitive Surgical, Inc.
^&
3
Johnson & Johnson MedTech
#@
4
Boston Scientific Corporation
$
5
STERIS plc
&@$
Combined Share$%

Market Dynamics

Local Players70%
Regional/Int'l30%

8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.

Company Profiles (Top 10 Players)
Company Name
Market Share
Headquarters
Founding Year
Core Market Focus
Stryker Corporation
Included in CR5 attribution; individual broad-scope share not publicly disclosedPortage, Michigan, United States1941Instruments, endoscopy, neuro cranial technologies, powered tools and Mako robotic enabling technology
Intuitive Surgical, Inc.
Included in CR5 attribution; individual broad-scope share not publicly disclosedSunnyvale, California, United States1995da Vinci robotic systems, instruments, accessories, service and digital surgical ecosystem
Johnson & Johnson MedTech
Included in CR5 attribution; individual broad-scope share not publicly disclosedNew Brunswick, New Jersey, United States1886Surgical instruments, energy, stapling, wound closure and robotic surgery development
Boston Scientific Corporation
Included in CR5 attribution; individual broad-scope share not publicly disclosedMarlborough, Massachusetts, United States1979Endoscopy, urology and minimally invasive procedural devices
STERIS plc
Included in CR5 attribution; individual broad-scope share not publicly disclosedDublin, Ireland; major U.S. operations in Mentor, Ohio1985Operating-room capital, sterilization, reprocessing, consumables and procedural support
Medtronic plc
Included in CR10 attribution; individual broad-scope share not publicly disclosedGalway, Ireland1949Surgical innovations, energy, stapling, visualization and Hugo robotic-assisted surgery
Olympus Corporation
Included in CR10 attribution; individual broad-scope share not publicly disclosedTokyo, Japan1919Endoscopy, surgical visualization, energy and minimally invasive procedural systems
Zimmer Biomet Holdings, Inc.
Included in CR10 attribution; individual broad-scope share not publicly disclosedWarsaw, Indiana, United States1927Orthopaedic surgical instruments, enabling technologies and ROSA robotic systems
Becton, Dickinson and Company
Included in CR10 attribution; individual broad-scope share not publicly disclosedFranklin Lakes, New Jersey, United States1897Surgical devices, infection-prevention products and procedure-related disposables
CONMED Corporation
Included in CR10 attribution; individual broad-scope share not publicly disclosedLargo, Florida, United States1970Electrosurgery, orthopaedics, smoke evacuation, endoscopic technologies and surgical instruments

Cross Comparison Parameters

The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.

Analysis Covered

Market Share Analysis:

Evaluates concentration, category leadership and fragmented specialist supplier participation.

Cross Comparison Matrix:

Benchmarks operating scale, recurring mix, growth and profitability indicators.

SWOT Analysis:

Assesses portfolio strengths, competitive vulnerabilities, opportunities and platform threats.

Pricing Strategy Analysis:

Compares capital, recurring consumables, leasing and enterprise contract economics.

Company Profiles:

Reviews market focus, technology positioning and commercial operating models.

CHAPTER 10 - REPORT TOC

Table of Contents

86Pages
34Chapters
10Companies Profiled
7Segmentation Types

Phase 1
Market Assessment Phase

11

Chapters

Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.

Phase 2
Go-To-Market Strategy Phase

15

Chapters

Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.

Complete Report Coverage

201+ detailed sections covering every aspect of the market

143

Assessment Sections

58

Strategy Sections

CHAPTER 11 - Our Approach

Research Methodology

Desk Research

  • Reviewed surgical procedure demand indicators
  • Mapped hospital and ASC infrastructure
  • Analyzed medtech segment revenue disclosures
  • Reviewed FDA and CMS policies

Primary Research

  • OR directors and perioperative leaders
  • ASC administrators and medical directors
  • Surgical procurement and value-analysis executives
  • OEM commercial and service leaders

Validation and Triangulation

  • Targeted 360 respondent validation design
  • Cross-checked supplier revenue attribution assumptions
  • Reconciled procedures with equipment intensity
  • Validated capital and consumable economics

CHAPTER 12 - FAQ

FAQs

Still have questions?

Our research team is here to help you find the right solution

Contact Research Team

CHAPTER 13 - Related Research

Explore Related Reports

Expand your market intelligence with complementary research across regions and adjacent markets.

Adjacent Reports

Related markets and complementary research

500+

Market Research Reports

50+

Countries Covered

15+

Industry Verticals

Want the full report and an analyst walkthrough?

Unlock the complete dataset, segmentation cuts, and competitive analysis—plus a discovery call that maps insights to your go-to-market priorities.

;